HRG (基因名), Histidine-rich glycoprotein (蛋白名), HRG_HUMAN.
产品名称:
Human HRG/ Histidine-rich glycoprotein ELISA Kit
富组氨酸糖蛋白
货号:
E2267h
商标:
EIAab®
监管等级:
别名:
Histidine-proline-rich glycoprotein, HPRG
检测方法:
ELISA
实验类型:
Sandwich
检测范围:
12.5-800ng/mL
灵敏度:
5.6ng/mL
特异性:
Natural and recombinant human Histidine-rich glycoprotein
样品类型:
Serum, plasma, tissue homogenates, cell culture supernates and other biological fluids
样品数据:
登录.
实验步骤:
研究领域:
-
精密度
批内差:已知浓度的3个样本在一个板子内重复检测20次,以评估批内精密度。
批内 CV: ≤4.7%
批间差:已知浓度的3个样本在不同的板子上重复测定5次,以评估测定批间精密度。
批间 CV: ≤8.2%
批内 CV: ≤4.7%
批间差:已知浓度的3个样本在不同的板子上重复测定5次,以评估测定批间精密度。
批间 CV: ≤8.2%
回收率
回收率:低、中和高浓度的分析物被掺入到血清或者血浆样本中,进行回收实验测定。
Sample Type | Average(%) | Recovery Range(%) |
Serum | 99 | 93-105 |
Plasma | 101 | 95-107 |
线性
线性:给定样本通过梯度稀释,每次稀释的测量值与理论值的比值。
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 107-117% | 89-99% | 103-115% | 105-117% |
EDTA plasma(n=5) | 99-111% | 88-101% | 102-112% | 82-92% |
heparin plasma(n=5) | 85-95%
| 100-108% | 107-116% | 108-117% |
通用注释
亚单元:
Interacts (via the HRR domain) with TPM1; the interaction appears to contribute to the antiangiogenic properties of the HRR domain. Interacts with THBS2; the interaction blocks the antiangiogenic effect of THBS2 with CD36 (By similarity). Interacts with THBS1 (via the TSP type I repeats); the interaction blocks the antiangiogenic effect of THBS1 with CD3. Interacts with PLG (via its Kringle domains); the interaction tethers PLG to the cell surface and enhances its activation. Interacts with HPSE; the interaction is enhanced at acidic pH, partially inhibits binding of HPSE to cell surface receptors and modulates its enzymatic activity. Interacts (via the HRR domain) with TMP1; the interaction partially mediates the antiangiogenic properties of HRG. Interacts with kappa and lambda light chains of IgG molecules. Interacts with ATP5A1; the interaction occurs on the surface of T-cells and alters their cell morphology in concert with CONA. Binds IgG molecules containing kappa and lambda light chains and inhibits the formation of insoluble immunoglobulin complexes. Interacts with F12; the interaction, which is enhanced in the presence of zinc ions and inhibited by heparin-binding to HRG, inhibits factor XII autoactivation and contact-initiated coagulation.
功能:
Plasma glycoprotein that binds a number of ligands such as heme, heparin, heparan sulfate, thrombospondin, plasminogen, and divalent metal ions. Binds heparin and heparin/glycosaminoglycans in a zinc-dependent manner. Binds heparan sulfate on the surface of liver, lung, kidney and heart endothelial cells. Binds to N-sulfated polysaccharide chains on the surface of liver endothelial cells. Inhibits rosette formation. Acts as an adapter protein and is implicated in regulating many processes such as immune complex and pathogen clearance, cell chemotaxis, cell adhesion, angiogenesis, coagulation and fibrinolysis. Mediates clearance of necrotic cells through enhancing the phagocytosis of necrotic cells in a heparan sulfate-dependent pathway. This process can be regulated by the presence of certain HRG ligands such as heparin and zinc ions. Binds to IgG subclasses of immunoglobins containing kappa and lambda light chains with different affinities regulating their clearance and inhibiting the formation of insoluble immune complexes. Tethers plasminogen to the cell surface. Binds T-cells and alters the cell morphology. Modulates angiogenesis by blocking the CD6-mediated antiangiongenic effect of thrombospondins, THBS1 and THBS2. Acts as a regulator of the vascular endothelial growth factor (VEGF) signaling pathway; inhibits endothelial cell motility by reducing VEGF-induced complex formation between PXN/paxillin and ILK/integrin-linked protein kinase and by promoting inhibition of VEGF-induced tyrosine phosphorylation of focal adhesion kinases and alpha-actinins in endothelial cells. Also plays a role in the regulation of tumor angiogenesis and tumor immune surveillance. Normalizes tumor vessels and promotes antitumor immunity by polarizing tumor-associated macrophages, leading to decreased tumor growth and metastasis.
亚细胞位置:
Secreted
该产品尚未在任何出版物中被引用。
[1].
人富组氨酸糖蛋白(HRG)ELISA试剂盒可以做多少个样本?
人富组氨酸糖蛋白(HRG)ELISA试剂盒分为2种规格,96孔和48孔。96孔的试剂盒,标曲和样本都做复孔的话,可以检测40个样本。96孔的试剂盒,标曲和样本都不做复孔的话,可以检测88个样本。
[2].
人富组氨酸糖蛋白(HRG)ELISA试剂盒使用视频?
人富组氨酸糖蛋白(HRG)ELISA试剂盒实验操作视频在以下网址中,对每一步的实验步骤都做了演示,方便实验员能更好地理解ELISA实验的过程。
https://www.eiaab.com.cn/lesson-tech/805.html
https://www.eiaab.com.cn/lesson-tech/805.html
[3].
人富组氨酸糖蛋白(HRG)ELISA试剂盒是放在-20℃冰箱保存吗?
EIAab的人富组氨酸糖蛋白(HRG)ELISA试剂盒,洗涤液、底物、终止液保存于4℃,其余试剂-20℃冰箱保存。
[4].
人富组氨酸糖蛋白(HRG)ELISA试剂盒原理?
双抗体夹心法:用纯化的抗体包被微孔板,制成固相抗体,往包被有固相抗体的微孔中依次加入标准品或受检样本、生物素化抗体、HRP标记的亲和素,经过彻底洗涤后用底物TMB显色。用酶标仪在450nm波长下测定吸光度(OD值),计算样本浓度。
竞争法:用纯化的抗体包被微孔板,制成固相抗体,往包被有固相抗体的微孔中依次加入标准品或受检样本和生物素标记的目标分析物,受检标本中抗原与生物素标记抗原竞争结合有限的抗体。再加入HRP标记的亲和素,经过彻底洗涤后用底物TMB显色。用酶标仪在450nm波长下测定吸光度(OD值),计算样本浓度。
竞争法:用纯化的抗体包被微孔板,制成固相抗体,往包被有固相抗体的微孔中依次加入标准品或受检样本和生物素标记的目标分析物,受检标本中抗原与生物素标记抗原竞争结合有限的抗体。再加入HRP标记的亲和素,经过彻底洗涤后用底物TMB显色。用酶标仪在450nm波长下测定吸光度(OD值),计算样本浓度。
[5].
人富组氨酸糖蛋白(HRG)ELISA试剂盒中需要使用的样品量是多少?
夹心法100μL/孔,竞争法50μL/孔。如样本浓度过高时,应对样本进行稀释,以使稀释后的样本符合试剂盒的检测范围,计算时再乘以相应的稀释倍数。
[6].
如何分析人富组氨酸糖蛋白(HRG)ELISA试剂盒数据?
建议标准曲线,并计算样本浓度。对于elisa的曲线拟合,一般建议采用4参数曲线拟合,4参数曲线拟合通常更适合免疫分析。推荐使用专业软件进行曲线拟合,例如curve expert 1.3。根据样本的OD值由标曲查出相应的浓度,再乘以稀释倍数;或用标准物的浓度与OD值计算出标曲的回归方程式,将样本的OD值代入方程式,计算出样本浓度,再乘以稀释倍数,即为样本的实际浓度。以下链接是curve expert 1.3软件拟合曲线的方法。
https://www.eiaab.com.cn/news/502/
https://www.eiaab.com.cn/news/502/
[7].
人富组氨酸糖蛋白(HRG)ELISA试剂盒中是否包含人和动物的副产物,是否包含感染的或者传染性原料如HIV等?
除了抗体和稀释液中的BSA,不含其它人和动物的副产物,也不含感染材料。
[8].
收集人富组氨酸糖蛋白(HRG)ELISA试剂盒血浆样本,用什么作为抗凝剂?
一般建议用EDTA和肝素作为抗凝剂。
[9].
人富组氨酸糖蛋白(HRG)ELISA试剂盒酶标板可以拆成几部分?拆的时候是否需要避光,无菌?
人富组氨酸糖蛋白(HRG)ELISA试剂盒酶标板是8×12孔条,可拆卸,板子可以拆成12条,注意避免孔污染,不需要避光和无菌。暂时不用的板子,放回原来装的袋子里,密封保存。
[10].
人富组氨酸糖蛋白(HRG)ELISA试剂盒样本如何保存?
尽量检测新鲜样本。若无新鲜样本,则4℃保存1周,-20℃保存1个月,-80℃保存2个月。
反馈墙
评论数 : 0
所有用户
所有用户
默认排序
默认排序
最近
早期
目前还没有评论。
通知
规格
数量
单价 (¥)
小计 1 (¥)
小计 2:
¥
规格
数量
单价 (¥)